Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation Technology
This is another important step in advancing Oral KORSUVAâ„¢ as a potential novel treatment for chronic pruritus by entering into this commercial formulation license.
Read More
